All news
/Funding
P3 Therapeutics is supported by the European Union under the InvestEU Fund
Non-dilutive European funding, stacked with seed equity, is part of how P3T stays capital-efficient while it completes preclinical development.
This operation benefits from support from the European Union under the InvestEU Fund, with the European Investment Fund and national development banks — SID Banka and HBOR — among the instruments involved.
For a preclinical company this matters twice over: it reduces dilution for early investors, and every grant or guarantee passes an external review of the science and the plan.
Seed investment opportunities based on equity remain open. Funds will be used for further SCM synthesis, completing preclinical development and IP protection.